Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Liver / HCC

Liver cancer and hepatocellular carcinoma.

Must-know

  1. 1

    Serial ctDNA and recurrence in hepatocellular carcinoma

    Zhu et al. Molecular Oncology. 2022.

    In this prospective study, preoperative ctDNA and the median variant allele fraction at baseline were independent predictors of recurrence-free survival.

    PMID 34543520DOI

A randomized ctDNA-guided hepatocellular carcinoma trial was not identified.

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

  • Tier 2 · Level 2 · Hepatology International · 2026-10-29 · Peer-reviewed · Verified

    Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma: a prospective multicenter cohort study

    Xu Y, et al. PMID 42955557 · doi 10.1007/s12072-026-11163-8

    Prospective multicenter cohort

    This prospective multicenter study enrolled 152 patients with BCLC stage 0-B hepatocellular carcinoma undergoing curative resection and monitored tumor-informed ctDNA MRD at 1, 4, and 7 months after surgery. Longitudinal MRD positivity (newly positive or persistently positive versus clearance or persistently negative) independently predicted recurrence (HR 12.45) and preceded radiologic recurrence in 87.5% of cases, with a median lead time of 86 days. Time-dependent AUCs for longitudinal MRD were 0.785-0.849, compared with 0.655-0.752 for microvascular invasion.

Accruing studies for Liver / HCC

Trials

No Colorectal and GI updates are on file for this filter.